Mark Goldberger has been named the first medical director  for Emerging and Pandemic Threat Preparedness at the 

Center for Biologics Evaluation and Research 

. In  his new position, Goldberger will assume responsibility for CBER’s pandemic flu  program and will coordinate and implement all programs related to developing  and evaluating products for emerging and pandemic threats. Goldberger will also  chair CBER’s Pandemic Influenza Steering Committee.  Employed at FDA since 1989, Goldberger  recently served as director of the Office of 

’s (CDER) Office of  Antimicrobial Products.

News

Mark Goldberger has been named the first medical director for Emerging and Pandemic Threat Preparedness at the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration.